Latest Conference Articles

December 5th 2020, 11:34pm

ASH Annual Meeting and Exposition

The anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

December 5th 2020, 11:31pm

ASH Annual Meeting and Exposition

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

December 5th 2020, 11:00pm

ASH Annual Meeting and Exposition

December 5, 2020 - VLS-101, a novel ROR1-targeted antibody-drug conjugate, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

December 5th 2020, 10:47pm

ASH Annual Meeting and Exposition

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

December 5th 2020, 9:30pm

ASH Annual Meeting and Exposition

Srdan Verstovsek, MD, PhD, discusses findings from the PV-AIM trial in polycythemia vera.

December 5th 2020, 9:30pm

ASH Annual Meeting and Exposition

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

December 5th 2020, 9:03pm

ASH Annual Meeting and Exposition

December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.

December 5th 2020, 9:00pm

ASH Annual Meeting and Exposition

December 5, 2020 - Axicabtagene ciloleucel demonstrated high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

December 5th 2020, 8:46pm

ASH Annual Meeting and Exposition

December 5, 2020 - Patients with previously untreated chronic lymphocytic leukemia /small lymphocytic lymphoma who received a placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease.

December 5th 2020, 8:20pm

ASH Annual Meeting and Exposition

December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.

December 5th 2020, 8:09pm

ASH Annual Meeting and Exposition

December 5, 2020 - The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.

December 5th 2020, 7:55pm

ASH Annual Meeting and Exposition

December 5, 2020 - Momelotinib improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis.

December 5th 2020, 7:47pm

ASH Annual Meeting and Exposition

December 5, 2020 - Patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors saw better overall survival, spleen response, and symptom response with higher doses of the telomerase inhibitor imetelstat.

December 5th 2020, 7:34pm

ASH Annual Meeting and Exposition

December 5, 2020 - Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area.

December 5th 2020, 7:30pm

ASH Annual Meeting and Exposition

December 5, 2020 - Selinexor demonstrated a clinical benefit in patients with relapsed/refractory diffuse large B-cell lymphoma, regardless of age.

December 5th 2020, 7:29pm

ASH Annual Meeting and Exposition

December 5, 2020 - The addition of navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

December 5th 2020, 6:55pm

ASH Annual Meeting and Exposition

December 5, 2020 - Azacitidine, was shown to significantly prolong overall survival and relapse-free survival in patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy.

December 5th 2020, 6:41pm

ASH Annual Meeting and Exposition

December 5, 2020 - KO-539, an oral, selective menin-inhibitor, demonstrated activity in patients with relapsed/refractory acute myeloid leukemia in preliminary findings from the ongoing first-in-human KOMET-001 trial.

December 5th 2020, 4:15pm

ASH Annual Meeting and Exposition

December 5, 2020 - Ruxolitinib was found to elicit a significantly higher overall response rate, a substantially greater improvement in failure-free survival, and greater symptom improvement versus best available therapy in patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.

November 22nd 2020, 5:30pm

ESMO Asia Congress

Sotorasib was well tolerated and led to disease control in the majority of patients with heavily pretreated KRAS G12C–mutant gastrointestinal malignancies.